U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Malignancy in giant cell tumor of bone

MedGen UID:
87263
•Concept ID:
C0334552
•
Neoplastic Process
Synonyms: bone giant cell sarcoma; Dedifferentiated Giant Cell Tumor; Dedifferentiated giant cell tumor; Dedifferentiated giant cell tumour; Giant Cell Bone Sarcoma; giant cell bone sarcoma; Giant cell sarcoma of bone; Giant Cell Sarcoma of Bone; giant cell sarcoma of bone; Giant Cell Sarcoma of the Bone; giant cell sarcoma of the bone; Giant cell tumor of bone, malignant; giant cell tumor of bone, malignant; giant cell tumor of bone, malignant (morphologic abnormality); giant cell tumour of bone, malignant; giant cell tumour of bone, malignant (morphologic abnormality); Malignancy in Giant Cell Tumor of Bone; malignancy in giant cell tumor of bone; Malignancy in Giant Cell Tumor of the Bone; malignancy in giant cell tumor of the bone; malignancy in giant cell tumour of the bone; Malignant Giant Cell Tumor of Bone; Malignant giant cell tumor of bone; malignant giant cell tumor of bone; malignant giant cell tumour of bone; Malignant osteoclastoma; Osteoclastoma, malignant; OSTEOCLASTOMA, malignant
SNOMED CT: Malignant giant cell tumor of bone (10069009); Malignant osteoclastoma (10069009); Giant cell tumor of bone, malignant (10069009); Osteoclastoma, malignant (10069009); Giant cell sarcoma of bone (10069009); Malignant giant cell tumor of bone (1295196005)
 
Monarch Initiative: MONDO:0006287

Definition

A malignant tumor that arises from the bone. It is characterized by the presence of an area of high grade sarcoma in an otherwise typical giant cell tumor (primary malignancy in giant cell tumor), or the presence of sarcoma in which the pre-existing giant cell tumor may or may not be apparent (secondary malignancy in giant cell tumor). [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMalignancy in giant cell tumor of bone

Professional guidelines

PubMed

Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts.
Stacchiotti S, Dürr HR, Schaefer IM, Woertler K, Haas R, Trama A, Caraceni A, Bajpai J, Baldi GG, Bernthal N, Blay JY, Boye K, Broto JM, Chen WT, Dei Tos PA, Desai J, Emhofer S, Eriksson M, Gronchi A, Gelderblom H, Hardes J, Hartmann W, Healey J, Italiano A, Jones RL, Kawai A, Leithner A, Loong H, Mascard E, Morosi C, Otten N, Palmerini E, Patel SR, Reichardt P, Rubin B, Rutkowski P, Sangalli C, Schuster K, Seddon BM, Shkodra M, Staals EL, Tap W, van de Rijn M, van Langevelde K, Vanhoenacker FMM, Wagner A, Wiltink L, Stern S, Van de Sande VM, Bauer S
Cancer Treat Rev 2023 Jan;112:102491. Epub 2022 Dec 6 doi: 10.1016/j.ctrv.2022.102491. PMID: 36502615
CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment.
Wen J, Wang S, Guo R, Liu D
Eur J Med Chem 2023 Jan 5;245(Pt 1):114884. Epub 2022 Oct 29 doi: 10.1016/j.ejmech.2022.114884. PMID: 36335744
The many faces of solitary fibrous tumor; diversity of histological features, differential diagnosis and role of molecular studies and surrogate markers in avoiding misdiagnosis and predicting the behavior.
Tariq MU, Din NU, Abdul-Ghafar J, Park YK
Diagn Pathol 2021 Apr 20;16(1):32. doi: 10.1186/s13000-021-01095-2. PMID: 33879215Free PMC Article

Curated

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Bone Cancer, 2024

Recent clinical studies

Etiology

Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
Palmerini E, Seeger LL, Gambarotti M, Righi A, Reichardt P, Bukata S, Blay JY, Dai T, Jandial D, Picci P
BMC Cancer 2021 Jan 22;21(1):89. doi: 10.1186/s12885-020-07739-8. PMID: 33482769Free PMC Article
Malignancy in giant cell tumor of bone.
Bertoni F, Bacchini P, Staals EL
Cancer 2003 May 15;97(10):2520-9. doi: 10.1002/cncr.11359. PMID: 12733152

Diagnosis

Malignancy in Giant Cell Tumor of Bone: A Review of the Literature.
Palmerini E, Picci P, Reichardt P, Downey G
Technol Cancer Res Treat 2019 Jan 1;18:1533033819840000. doi: 10.1177/1533033819840000. PMID: 30935298Free PMC Article
Primary malignancy in giant cell tumor of thoracic vertebrae: A case report.
Yu H, Shi R, Peng ZG, Yu BH, Cui JL
Medicine (Baltimore) 2018 Jul;97(28):e11484. doi: 10.1097/MD.0000000000011484. PMID: 29995810Free PMC Article
An extremely rare case of primary malignancy in giant cell tumor of bone, arising in the right femur and harboring H3F3A mutation.
Tsukamoto Y, Futani H, Kihara T, Watanabe T, Kumanishi S, Matsuo S, Hirota S, Ueda T, Yamamoto H, Yoshiya S
Pathol Res Pract 2018 Sep;214(9):1504-1509. Epub 2018 Jun 28 doi: 10.1016/j.prp.2018.06.015. PMID: 29970305
Malignancy in giant cell tumor of bone.
Bertoni F, Bacchini P, Staals EL
Cancer 2003 May 15;97(10):2520-9. doi: 10.1002/cncr.11359. PMID: 12733152

Therapy

Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
Palmerini E, Seeger LL, Gambarotti M, Righi A, Reichardt P, Bukata S, Blay JY, Dai T, Jandial D, Picci P
BMC Cancer 2021 Jan 22;21(1):89. doi: 10.1186/s12885-020-07739-8. PMID: 33482769Free PMC Article
Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab.
Tsukamoto S, Righi A, Vanel D, Honoki K, Donati DM, Errani C
Jpn J Clin Oncol 2017 Nov 1;47(11):1090-1096. doi: 10.1093/jjco/hyx112. PMID: 29048579

Prognosis

Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
Palmerini E, Seeger LL, Gambarotti M, Righi A, Reichardt P, Bukata S, Blay JY, Dai T, Jandial D, Picci P
BMC Cancer 2021 Jan 22;21(1):89. doi: 10.1186/s12885-020-07739-8. PMID: 33482769Free PMC Article
Malignancy in Giant Cell Tumor of Bone: A Review of the Literature.
Palmerini E, Picci P, Reichardt P, Downey G
Technol Cancer Res Treat 2019 Jan 1;18:1533033819840000. doi: 10.1177/1533033819840000. PMID: 30935298Free PMC Article
An extremely rare case of primary malignancy in giant cell tumor of bone, arising in the right femur and harboring H3F3A mutation.
Tsukamoto Y, Futani H, Kihara T, Watanabe T, Kumanishi S, Matsuo S, Hirota S, Ueda T, Yamamoto H, Yoshiya S
Pathol Res Pract 2018 Sep;214(9):1504-1509. Epub 2018 Jun 28 doi: 10.1016/j.prp.2018.06.015. PMID: 29970305
Malignancy in giant cell tumor of bone.
Bertoni F, Bacchini P, Staals EL
Cancer 2003 May 15;97(10):2520-9. doi: 10.1002/cncr.11359. PMID: 12733152

Clinical prediction guides

Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
Palmerini E, Seeger LL, Gambarotti M, Righi A, Reichardt P, Bukata S, Blay JY, Dai T, Jandial D, Picci P
BMC Cancer 2021 Jan 22;21(1):89. doi: 10.1186/s12885-020-07739-8. PMID: 33482769Free PMC Article
Development of high-grade osteosarcoma in a patient with recurrent giant cell tumor of the ischium while receiving treatment with denosumab.
Tsukamoto S, Righi A, Vanel D, Honoki K, Donati DM, Errani C
Jpn J Clin Oncol 2017 Nov 1;47(11):1090-1096. doi: 10.1093/jjco/hyx112. PMID: 29048579

Recent systematic reviews

Malignancy in Giant Cell Tumor of Bone: A Review of the Literature.
Palmerini E, Picci P, Reichardt P, Downey G
Technol Cancer Res Treat 2019 Jan 1;18:1533033819840000. doi: 10.1177/1533033819840000. PMID: 30935298Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    • NCCN, 2024
      NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Bone Cancer, 2024

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...